Business
OPKO Health, Inc. Announces Proposed Offering of Common Stock
MIAMI, Oct. 22, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (“OPKO Health” or the “Company”) (NASDAQ:OPK) today announced that, subject to market and other
About this update from Opko Health, Inc.
[{"type":"text","content":"MIAMI, Oct. 22, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (“OPKO Health” or the “Company”) (NASDAQ:OPK) today announced that, subject to market and other conditions, it intends to offer and sell up to $100 million of shares of its common stock (the “Shares”) in an underwritten public offering. The Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of Shares to be issued and sold in the offering.\n The Company intends to use the net proceeds received from the offering of the Shares to fund research and development to further develop and commercialize its portfolio of proprietary pharmaceutical and diagnostic products and for working capital, capital expenditures, acquisitions and other general corporate purposes. Jefferies LLC, Piper Jaffray & Co. and Guggenheim Securities, LLC will act as joint book-running managers for the offering. The offering of the Shares will be made by means of a prospectus supplement to the prospectus forming a part of the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-229400) filed with the Securities and Exchange Commission (the “SEC”) on January 28, 2019 and other related documents. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY, 10022, by email at [email protected] or by phone at +1 877 821 7388; Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by email at [email protected] or by phone: 1-800-747-3924; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by email at [email protected] or by phone at +1 212 518 5548. Before you invest, you should read the prospectus supplement and the accompanying base prospectus along with other documents that the Company has filed with the SEC for more complete information about the Company and these offerings. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, the Shares or any other securities, nor wil...